Heart Transplant Market Report 2026

The heart transplant market size has grown strongly in recent years. It will grow from $12.62 billion in 2025 to $13.77 billion in 2026 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to increasing prevalence of end-stage heart failure, expansion of cardiac specialty centers, improvements in surgical techniques, growing availability of transplant programs, rising use of mechanical circulatory support.

The heart transplant market size is expected to see strong growth in the next few years. It will grow to $20.08 billion in 2030 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to increasing investments in artificial heart research, rising demand for long-term cardiac support solutions, expansion of donor management technologies, growing focus on precision post-transplant care, increasing adoption of digital health monitoring. Major trends in the forecast period include increasing adoption of ventricular assist devices, rising use of advanced transplant monitoring systems, growing integration of digital patient management platforms, expansion of artificial heart technologies, enhanced focus on post-transplant outcomes.

The increasing prevalence of cardiovascular diseases is expected to drive the growth of the heart transplant market going forward. Cardiovascular diseases encompass a broad range of conditions that affect the heart and blood vessels. A heart transplant is considered a last-line treatment for patients with end-stage heart failure who do not respond to conventional therapies, as it helps improve quality of life and extend survival. For example, in September 2024, according to the British Heart Foundation, a UK-based cardiovascular research charity, around 7.6 million people in the UK were living with heart and circulatory diseases, including 4 million men and 3.6 million women. This figure is projected to rise by 1 million by 2030 and by 2 million by 2040 compared to current levels. Consequently, the rising prevalence of cardiovascular diseases is supporting the growth of the heart transplant market.

Companies operating in the heart transplant market are increasingly concentrating on the development of innovative solutions, such as advanced heart preservation technologies, to enhance transplant success rates and patient outcomes. These technologies significantly extend the duration for which a heart can be preserved outside the body compared to conventional ice storage, thereby reducing post-transplant complications and improving outcomes. For instance, in May 2023, Xvivo Perfusion AB, a Sweden-based medical technology company, received approval from the U.S. Food and Drug Administration (FDA) for an Investigational Device Exemption (IDE) application for its heart preservation technology, enabling the initiation of the PRESERVE Clinical Trial. This prospective, multicenter, single-arm, open-label study evaluates heart transplants using non-ischemic preservation from extended donors, including Donation after Circulatory Death (DCD) hearts. A key distinguishing feature of XVIVO’s technology is its non-ischemic hypothermic perfusion system, which uses cold, oxygenated perfusion to maintain donor heart viability during transportation.

In August 2024, Getinge, a Sweden-based medical technology and healthcare solutions provider, acquired Paragonix Technologies for an undisclosed amount. This acquisition was intended to strengthen Getinge’s portfolio in organ preservation and transport solutions, with a focus on improving outcomes in transplant procedures. Paragonix Technologies, a US-based company, specializes in the design, manufacture, and commercialization of organ transplant transport devices.

Major companies operating in the heart transplant market are Mayo Clinic, Cleveland Clinic, Massachusetts General Hospital, Johns Hopkins Hospital, NewYork-Presbyterian Hospital, Cedars-Sinai Medical Center, Stanford Health Care, Baylor St Lukes Medical Center, The Texas Heart Institute, Duke University Hospital, UCLA Medical Center, Mount Sinai Hospital, Brigham and Womens Hospital, University of Pittsburgh Medical Center, Houston Methodist Hospital, Northwestern Memorial Hospital, NYU Langone Health, Toronto General Hospital, Royal Papworth Hospital, Harefield Hospital.

North America was the largest region in the heart transplant market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the heart transplant market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the heart transplant market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the heart transplant market by increasing costs of imported surgical equipment, artificial heart components, ventricular assist devices, and advanced monitoring systems. Cardiac institutes and transplant hospitals in North America and Europe are most affected due to reliance on specialized imported technologies, while Asia-Pacific faces higher capital costs for advanced transplant infrastructure. These tariffs are increasing procedural costs and limiting accessibility. However, they are also supporting local device development, regional manufacturing initiatives, and innovation in cost-optimized cardiac support technologies.

The heart transplant market research report is one of a series of new reports that provides heart transplant market statistics, including heart transplant industry global market size, regional shares, competitors with a heart transplant market share, detailed heart transplant market segments, market trends and opportunities, and any further data you may need to thrive in the heart transplant industry. This heart transplant market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A heart transplant is a surgical procedure in which a failing or diseased heart is removed and replaced with a healthy donor heart. It is a complex, life-saving treatment used for patients with end-stage heart failure or other serious cardiac conditions.

The primary types of heart transplant-related procedures include total artificial heart implantation, biventricular pacing, ventricular assist devices, and other approaches. A total artificial heart is a mechanical system designed to fully replace both the left and right ventricles of the human heart. These procedures involve different transplant categories, such as autografts, allografts, and others. The key end users of heart transplant services include hospitals, cardiac institutes, and other healthcare facilities.

The heart transplant market includes revenues earned by entities by providing services such as patient evaluation and selection, waitlist management, donor heart procurement, transplant surgery, immunosuppression management, psychosocial support and complications management services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.